Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022

Rhea-AI Summary

Organon (NYSE: OGN) will release its second quarter 2022 financial results on August 4, 2022, prior to a conference call scheduled for 8:30 a.m. EDT. The call will be accessible via webcast on the company's website, and a replay will be available two hours post-event. Organon focuses on women's healthcare with over 60 medicines and products in its portfolio. The company aims to improve women's health through innovation and partnerships in growing international markets.

Positive

• Strong cash flows from a diverse portfolio exceeding 60 products.
• Focus on expanding biosimilars and established medications.
• Opportunities for collaboration with biopharmaceutical companies.

Negative

• None.

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2022 financial results on August 4, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance using conference ID# 58511-993 and by clicking on this link: https://conferencingportals.com/event/ZGyfDfjk. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

About Organon
Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005036/en/

Organon Media Contacts:

Karissa Peer

(614) 314-8094



Kate Vossen

(732) 675-8448



Organon Investor Contacts:

Jennifer Halchak

(201) 275-2711



Edward Barger

(267) 614-4669

Source: Organon & Co.

FAQ

When will Organon release its Q2 2022 financial results?

Organon will release its Q2 2022 financial results on August 4, 2022.

What time is Organon's conference call for Q2 2022 results?

The conference call is scheduled for 8:30 a.m. EDT on August 4, 2022.

How can I access Organon's Q2 2022 financial results call?

The call can be accessed via webcast on Organon's investor relations website.

What is Organon focusing on in its business strategy?

Organon is focused on improving women's health and expanding its biosimilars business.

How many products does Organon have in its portfolio?

Organon has over 60 medicines and products in its portfolio.